Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

NCT01416831 | Active Not Recruiting Phase 2 Results

• 1 other identifier: 11-062A
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL-2 to patients treated with high-dose IL-2 along with radiation therapy.

Conditions

Metastatic Melanoma

Keywords

metastatic melanoma; IL-2; Interleukin 2; Radiation; Stereotactic Body Radiation Treatment; SBRT; Immunotherapy

Outcome Measures

Primary Outcomes (1)

• Best Overall Tumor Response of High Dose IL-2 vs. SBRT + High Dose IL-2

  Determine the best overall tumor response rate of high dose IL-2 versus SBRT + high-dose IL-2 using RECIST v1.1 assessed by CT/MRI, criteria applied to all target and non-target lesions with the exclusion of sites treated with SBRT. For patients who have SBRT after progression on IL-2 monotherapy, the response rate will be recorded, but not counted as a response for the primary objective. Overall response rate (ORR) includes all measurable and non-measurable target lesions except the lesions treated by SBRT, which were assessed separately. Both CT and positron emission tomography imaging were employed to assess response. Complete Response: disappearance of all target/non-target lesions and no abnormalities on PET; Partial Response: ≥30% decrease in sum of longest diameter (LD) of target lesions; Progressive Disease: ≥20% increase in sum of LD recorded since tx start or appearance of ≥1 new lesions; Stable Disease: Neither qualifying for PR nor PD since tx started.

  At the end of Cycle 2 (Week 14).

Secondary Outcomes (1)

• Response Rate in Crossover Patients

  7 weeks following Cycle 2 (Week 21).

Study Arms (2)

Arm A: IL-2 Monotherapy

ACTIVE COMPARATOR

Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2. Crossover patients will be included in Arm A.

Drug: High-dose IL-2

Arm B: SBRT + IL-2

EXPERIMENTAL

Patients will receive two doses of radiation before receiving high-dose IL-2.

Other: Radiation therapy and high-dose IL-2

Interventions

Radiation therapy and high-dose IL-2 OTHER

Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.

Also known as: Interleukin 2, Stereotactic Body Radiation Therapy (SBRT)

Arm B: SBRT + IL-2

High-dose IL-2 DRUG

IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.

Also known as: Interleukin 2, Stereotactic Body Radiation Therapy (SBRT).

Arm A: IL-2 Monotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histological confirmation of melanoma will be required by previous biopsy or cytology.
• Patients must be ≥ 18 years of age.
• Patients must have tumors amenable to SBRT in lungs, mediastinum, chest wall, bones (other than long bones), or liver (inclusive of immediately adjacent masses), 1 - 3 foci; no minimum size, but none greater than 7 cm. Patients may have other metastases but only a maximum of 3 will be treated.
• ECOG performance status of 0-1.
• Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment. The results of this test must be negative in order for the patient to be eligible. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy.
• Patients must sign a study-specific consent form.

You may not qualify if:

• No metastatic site amenable to SBRT.
• Patients with brain metastases not candidates for radiosurgery.
• Previous radiation to sites proposed for radiation as part of this study.
• Patients with active systemic, pulmonary, or pericardial infection.
• Pregnant or lactating women.
• Evidence of ischemia on exercise tolerance test, stress thallium study, or baseline EKG.
• DLCO, FEV1 or FEV1/FVC less than 70% of predicted due to clinically significant underlying pulmonary disease. For any pulmonary function test values less than predicted values, the PI will review, and document the patient's suitability for high dose IL-2 therapy.
• WBC \< 3.0 x 109/L
• Hgb \< 9.0 g/dL
• AST/ALT \> 3 times the upper limit of the normal range
• total bilirubin \> 1.9 g/dL
• creatinine \> 1.9 g/dL
• Patient requires chronic steroids.

Sponsors & Collaborators

• Providence Health & Services: lead
• Prometheus Laboratories: collaborator

Study Sites (1)

Providence Cancer Center

Portland, Oregon, 97213, United States

Location

Related Publications (2)

• Curti B, Crittenden M, Seung SK, Fountain CB, Payne R, Chang S, Fleser J, Phillips K, Malkasian I, Dobrunick LB, Urba WJ. Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma. J Immunother Cancer. 2020 May;8(1):e000773. doi: 10.1136/jitc-2020-000773.

  PMID: 32467299 DERIVED

• Sckisel GD, Mirsoian A, Minnar CM, Crittenden M, Curti B, Chen JQ, Blazar BR, Borowsky AD, Monjazeb AM, Murphy WJ. Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. J Immunother Cancer. 2017 Apr 18;5:33. doi: 10.1186/s40425-017-0235-4. eCollection 2017.

  PMID: 28428882 DERIVED

MeSH Terms

Conditions

Melanoma

Interventions

Radiotherapy; Interleukin-2; Radiosurgery

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Therapeutics; Interleukins; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Lymphokines; Proteins; Biological Factors; Stereotaxic Techniques; Neurosurgical Procedures; Surgical Procedures, Operative; Investigative Techniques

Results Point of Contact

• Title: Brendan Curti, M.D.
• Organization: Earle A. Chiles Research Institute, Providence Cancer Institute

brendan.curti@providence.org

503-215-6588

Study Officials

• Brendan Curti, M.D.

  Providence Health & Services

  PRINCIPAL INVESTIGATOR

• Steven K. Seung, M.D.

  Providence Health & Services

  PRINCIPAL INVESTIGATOR

• Marka Crittenden, MD, PhD

  Providence Health & Services

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2011
• First Posted: August 15, 2011
• Study Start: July 1, 2011
• Primary Completion: April 5, 2017
• Study Completion (Estimated): December 1, 2026
• Last Updated: April 24, 2026
• Results First Posted: November 15, 2022

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)